Diagnostik und Therapie maligner Ovarialtumoren 2005: Die Empfehlungen der Kommission Ovar der AGO

Zusammenfassung

Die Mitglieder der Kommission Ovar der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) haben in einem Konsensusverfahren aktuelle Empfehlungen zu Diagnostik und Therapie der malignen Ovarialtumoren erarbeitet und diese mit Evidenzlevel (LoE) und Empfehlungsgrad (GoR) der Canadian Task Force for Preventive Health Care bewertet. Eine Kurzfassung dieser Leitlinien, die die wichtigsten Publikationen bis Juni 2005 berücksichtigt, wird im Folgenden dargestellt.

Abstract

Recommendations for diagnosis and treatment of malignant ovarian tumors with regard to the most recent data were worked out in a consensus process and valued by level of evidence (LoE) and grade of recommendation (GoR) of the Canadian Task Force for Preventive Health Care by the members of the Kommission Ovar der Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) in june 2005. A short version of these guidelines is presented.

Schlüsselwörter

Leitlinien - Therapie - maligne Ovarialtumoren - Kommission Ovar der AGO

Key words

guidelines - therapy - malignant ovarian tumors - commission Ovar the AGO

Literatur

• 1 Antoniou A, Pharoah P D, Narod S. et al . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.  Am J Hum Genet. 2003;  72 1117-1130
• 2 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland .Krebs in Deutschland - Häufigkeiten und Trends. 4. Ausgabe, Saarbrücken 2004
• 3 Bell D A, Longacre T A, Prat J, Kohn E C, Soslow R A, Ellenson L H, Malpica A, Stoler M H, Kurman R J. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.  Hum Pathol. 2004;  35 934-948
• 4 Bell R, Petticrew M, Luengo S, Sheldon T A. Screening for ovarian cancer: a Systematic review. Health Technology Assessment 2:2, Southampton 1998
• 5 Du Bois A, Lück H J, Meier W, Adams H P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
• 6 Du Bois A, Meier W, Lück H J, Emons G. et al . Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.  Annals of Oncology. 2002;  13 251-257
• 7 Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.  J Clin Oncol. 2002;  20 1248-1259
• 8 Van der Burg M E, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave A J, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.  N Engl J Med. 1995;  332 629-634
• 9 Cramer D W, Hutchison G B, Welch W R, Scully R E, Knapp R C. Factors affecting the association of oral contraceptives and ovarian cancer.  N Engl J Med. 1982;  307 1047-1051
• 10 Crawford S C, Vasey P A, Paul J, Hay A, Davis J A, Kaye S B. Scottish Gynaecologic Cancer Trals Group .Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. Proc Am Soc Clin Oncol 2005; #5003 Abstract
• 11 Elit L, Bondy S J, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer.  Gynecol Oncol. 2002;  87 260-267
• 12 Gordon A N, Fleagle J T, Guthrie D. et al . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicn versus topotecan.  J Clin Oncol. 2001;  19 3312-3322
• 13 Harter P, Breitbach G P, Tanner B, Sehouli J, Heilmann V, Lueck H J, Kuhn W, Wimberger P, Ortmann O, du Bois A. Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Group (AGO-OVAR). Proc Am Soc Clin Oncol 2005; #5004 Abstract
• 14 International Collaborative Ovarian Neoplasm (ICON) Collaborators . International Collaborative Ovarian Neoplasm Trial-1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.  J Natl Cancer Inst. 2003;  95 125-132
• 15 The ICON and AGO Collaborators . Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.  The Lancet. 2003;  361 2099-2106
• 16 Kommission Ovar der AGO .Ovarialkarzinom State of the Art. Juni 2005. CD-ROM, (ISBN 3-00-016-495-2)
• 17 Lecuru F, Desfeux P, Camatte S, Bissery A, Robin F, Blanc B, Querleu D. Stage I ovarian cancer: comparison of laparoscopy and laparotomy on staging and survival.  Eur J Gynaecol Oncol. 2004;  25 571-576
• 18 Mateo R, Singh G, Jabbour N, Palmer S, Genyk Y, Roman L. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors.  Gynecol Oncol. 2005;  97 266-270
• 19 Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H, Sakuragi N. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer.  Gynecol Oncol. 2004;  94 161-166
• 20 Benedetti-Panici P B, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi R S, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.  J Natl Cancer Inst. 2005;  97 560-566
• 21 Pfisterer J, Plante M, Vergote I, du Bois A, Eisenhauer E. for the AGO-OVAR, NCIC CTG & EORTC GCG . Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.  Int J Gynecol Cancer. 2005;  15 (Suppl 1) 36-41
• 22 Piccart M J, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J A, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.  Int J Gynecol Cancer. 2003;  13 (Suppl 2) 144-148
• 23 Rose P G, Nerenstone S, Brady M F, Clarke-Pearson D, Olt G, Rubin S C, Moore D H, Small J M. Secondary surgical cytoreduction for advanced ovarian carcinoma.  N Engl J Med. 2004;  351 2489-2497
• 24 Rosen B, Kwon J, Fung Kee Fung M. et al . Systematic review of management options for women with a hereditary predisposition to ovarian cancer.  Gynecol Oncol. 2004;  93 280
• 25 Sandercock J, Parmar M KB, Torri V, Quian W. First-line treatment for advanced Ovarian cancer: paclitaxel, platinum and the evidence.  Br J Cancer. 2002;  87 815-824
• 26 Schumer S T, Cannistra S A. Granulosa cell tumor of the ovary.  J Clin Oncol. 2003;  21 1180-1189
• 27 Seidman J D, Soslow R A, Vang R. et al . Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images.  Hum Pathol. 2004;  35 918-933
• 28 Tavassoli F A, Devilee P. World Health Organization Classification of Tumours .Pathology & Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon 2003
• 29 Tingulstad S, Skjeldestad F E, Halvorsen T B, Hagen B. Survival and prognostic factors in patients with ovarian cancer.  Obstet Gynecol. 2003;  101 885-891
• 30 Trimbos J B, Vergote I, Bolis G, Vermorken J B, Mangioni C, Madronal C. et al . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - Adjuvant Chemotherapy in Ovarian Neoplasmn Trial.  J Natl Cancer Inst. 2003;  95 113-125
• 31 Vasey P A, Jayson G C, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye S B. Scottish Gynaecological Cancer Trials Group . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.  J Natl Cancer Inst. 2004;  96 1682-1691
• 32 Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore M E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Trope C G. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.  Lancet. 2001;  357 176-182
• 33 Whittemore A S, Harris R, Itnyre J. Collaborative Ovarian Cancer Group . Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epihelial ovarian cancers in white women.  Am J Epidemiol. 1992;  136 1184-1203
• 34 De Wit R, Roberts J T, Wilkinson P M, de Mulder P HM, Mead G M, Fossa S D, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of Three or Four Cycles of Bleomycin, Etoposide and Cisplatin Chemotherapy and for a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitouinary Tract Cancer Cooperative Group and the Medical Research Council.  J Clin Oncol. 2001;  19 1629-1640
• 35 Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of childbearing age.  Br J Obstet Gynaecol. 1997;  104 1030-1035